The connection is that both use MSCs as therapies, with this slide highlighting the other biotech's deficient process for commercial-scale manufacturing of MSCs vs. the Cymerus process.
Ann: Initial Director's Interest Notice - Kilian Kelly, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.005(3.13%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $13.43K | 83.19K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50193 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 64370 | 5 |
View Market Depth
| Last trade - 12.12pm 26/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |